Advertisement

Selective Decontamination of the Digestive Tract as a Method of Infection Prevention in Granulocytopenic Patients; A Follow-Up Study in 102 Patients

  • H. G. de Vries-Hospers
  • D. Th. Sleijfer
  • N. H. Mulder
  • H. O. Nieweg
  • D. van der Waaij
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

Several years ago selected decontamination of the digestive tract (SDD) (1) was proposed for prevention of infection in the neutropenic patient. This method aims at elimination of potentially pathogenic bacteria from the gut without affecting the anaerobic microflora. From the infection preventing point of view this is acceptable because anaerobic bacteria seldomly cause infections in the granulocytopenic patient (2). On the other hand anaerobes have been shown to play a key role in the normal interbacterial balance. The presence of an intact anaerobic flora in the gut hinders colonization by potentially pathogenic bacteria such as aerobic Gram-negative bacilli, yeasts and staphylococci. The mechanism which prevents colonization by potentially pathogenic microorganisms (ppmo) in the gut has been first described by Van der Waaij who introduced the term colonization resistance (CR) (3). The above mentioned ppmo are also the most frequently involved ppmo in infections in the neutropenic patient (2). The majority of these infections find their porte of entry in the digestive tract (4). In order to prevent infection it is therefore attempted to clear the digestive tract from these potentially pathogenic microorganisms. Moreover it was attempted to preserve an intact CR, so that the natural barrier against colonization is at least maintained. It may even be artificially increased by oral administration of antimicrobial agents which are able to eliminate selectively certain ppmo. In a prospective controlled clinical trial SDD appeared to be effective in reducing the infection frequency (1). The difference however was only significant at granulocyte levels below 0.5x109/l.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sleijfer DT, Mulder NH, De Vries-Hospers HG, et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 1980; 16: 859–69.PubMedCrossRefGoogle Scholar
  2. 2.
    Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients. Cancer 1978; 41: 1610–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Van der Waaij D, Berghuis-de Vries JM, Lekkerkerk-van der Wees JEC. Colonization resistance of the digestive tract in conventional and antibiotic treated animals. J Hyg Camb 1971; 69: 405–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquired infections. Ann Intern Med 1972; 77: 707–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Gale RP, Cline MJ. High remission induction rate in acute myeloid leukemia. Lancet 1977;i:497–9.CrossRefGoogle Scholar
  6. 6.
    Smith PB, Tomforde KM, Rhoden DL, Balows A. API-system: A multitube method for indentification of Enterobacteriaceae. Appl Microbiol 1972; 24: 449–52.PubMedCentralPubMedGoogle Scholar
  7. 7.
    De Vries EGE, Mulder NH, Houwen BH, De Vries-Hospers HG. Enteral nutrition by nasogastric tube in adult patients treated with intensive chemotherapy for acute leukemia. Am J Clin Nutrition 1982; 35: 1490–6.Google Scholar
  8. 8.
    De Vries-Hospers HG, Van der Waaij D. Amphotericin B concentrations in saliva after application of 2% amphotericin B in Orabase. Infection 1978; 6: 16–20.PubMedCrossRefGoogle Scholar
  9. 9.
    De Vries-Hospers HG, Van de Waaij D. Saliva concentrations of amphotericin B following its use as an oral lozenge. Infection 1980; 8: 63–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Wade JC, De Jongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs nalidixic acid. J Inf Dis 1983; 147: 62–34.CrossRefGoogle Scholar
  11. 11.
    Kurrle E, Bhaduri S, Krieger D, Pflieger H, Heimpel H. Antimicrobial prophylaxis in acute leukemia: prospective randomized study to compare two methods of selective decontamination. Klin Wochenschrift 1983; 61: 691–8.CrossRefGoogle Scholar
  12. 12.
    Guiot HFL, Van der Meer JWM, Van Furth R. Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Inf Dis 1981; 143: 644–54.CrossRefGoogle Scholar
  13. 13.
    Guiot HFL, Van den Broek PJ, Van der Meer JWM, Van Furth R. Selective antimicrobial modulation of the intestinal flora of patients with acute non-lymphocytic leukemia: a double blind, placebo controlled study. J Inf Dis 1983; 147: 615–23.CrossRefGoogle Scholar
  14. 14.
    De Vries-Hospers HG, Sleijfer DT, Mulder NH, Van der Waaij D, Nieweg HO, Van Saen HKF. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. AAC 1981; 19: 813–20.CrossRefGoogle Scholar
  15. 15.
    Rozenberg-Arska A, Dekker AW, Verhoef J. Colistin and trimethoprim-sulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukemia. Decrease in the emergence of resistant bacteria. Infection 1983; 11: 167–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • H. G. de Vries-Hospers
  • D. Th. Sleijfer
  • N. H. Mulder
  • H. O. Nieweg
  • D. van der Waaij

There are no affiliations available

Personalised recommendations